Suppr超能文献

ESCALOX 试验预研究的 VMAT、IMRT 和螺旋断层调强放疗计划比较报告。

Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study.

机构信息

Department of Radiation Oncology, Technical University of Munich (TUM), School of Medicine, Klinikum Rechts Der Isar, Ismaninger Straße 22, 81675, Munich, Germany.

Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, Zurich, Switzerland.

出版信息

Radiat Oncol. 2020 Nov 2;15(1):253. doi: 10.1186/s13014-020-01693-2.

Abstract

BACKGROUND

The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques.

METHODS

CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95% = 77 Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids.

RESULTS

All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT.

CONCLUSION

Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT. Trial registration ClinicalTrials.gov Identifier: NCT01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01.

摘要

背景

ESCALOX 试验是一项多中心、随机前瞻性剂量递增研究,用于头颈部癌症。因此,治疗计划的可行性通过不同的治疗计划系统(TPS)和放射治疗(RT)技术至关重要。我们假设通过不同的 TPS 和 RT 技术,同时整合升压(SIB)体积的剂量分布具有可比性,同时符合约束条件。

方法

前研究(高达 77Gy)的前 6 名患者(均为男性,平均年龄:61.3 岁)的 CT 数据集用于比较 IMRT、VMAT 和螺旋断层放疗(HT)。口咽是主要肿瘤部位。三步 SIB(77Gy、70Gy、56Gy)归一化后 D95%=77Gy。比较 PTV 的覆盖率(CVF)、正常组织适形指数(HTCI)、适形度指数(CN)和剂量均匀性(HI),以及腮腺的构象指数(COIN)。

结果

所有 RT 技术均能达到良好的覆盖。对于 SIB77Gy,IMRT 和 VMAT 的 CVF 最好,HT 达到最高的 CN,其次是 VMAT 和 IMRT。HT 达到了良好的 HTCI 值,与其他两种技术相比,HI 也较好。对于 SIB70Gy,IMRT 的 CVF 最好。HTCI 有利于 HT,继而 CN 也有利于 HT。对于 SIB56Gy,CVF 结果相当。适形性有利于 VMAT,这在 HTCI 和 CN 中可以看出。同侧和对侧腮腺的 Dmean 有利于 HT。

结论

不同的 TPS 剂量递增可靠地达到了较高的计划质量。尽管 HT 计划在覆盖范围、一致性和均匀性方面取得了非常好的结果,但 TPS 也为 IMRT 和 VMAT 取得了可接受的结果。试验注册:ClinicalTrials.gov 标识符:NCT01212354,EudraCT-No.:2010-021139-15。ARO:ARO 14-01。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/541c/7607845/0f51479b3069/13014_2020_1693_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验